Literatur
-
1
Hortobagyi G N. et al .
Randomized trial of high-dose chemotherapy and
blood cell autographs of high-risk primary breast carcinoma.
JNCI.
2000;
92
225-233
-
2
Peters W. et al .
A prospective, randomized comparison to
two doses of combination alkylating agents (AA) as consolidation
after CAF in high-risk primary breast cancer involving ten ore more
axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC
MA-13.
Proc ASCO.
1999;
18
1a
-
3
Rodenhuis S. et al .
Randomised trial of high-dose chemotherapy and
haematopoietic progenitor cell support in operable breast cancer
with extensive axillary lymph node involvement.
Lancet.
1998;
352
515-521
-
4
Bergh J. et
al .
Tailored fluorouracil, epirubicin, and cyclophosphamide
compared with marrow-supported high-dose chemotherapy as adjuvant
treatment for high-risk breast cancer: a randomised trial.
Lancet.
2000;
356
1384-1391
-
5
Rodenhuis S. et al .
Randomised phase III study of high-dose
chemotherapy with cyclophosphamide, thiotepa and carboplatin in
operable breast cancer with 4 or more axillary lympho nodes.
Proc ASCO.
2000;
19
286
Prof. Dr. med. D. K. Hossfeld
Abteilung Onkologie-Hämatologie der
Klinik und Poliklinik für Innere Medizin, Universitätsklinikum
Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
